Pharma needs to improve public understanding of innovative drugs' true costs

04/7/2014 | American City Business Journals

The Impact 2020 report released Friday calls on Massachusetts biotech leaders to step up and influence the debate over health care costs to protect high reimbursement rates for breakthrough therapies and preserve funding from the NIH to discover new drugs. Learning how to communicate new drugs' value and their development costs will be vital to that effort, Don Seiffert writes.

View Full Article in:

American City Business Journals

Published in Briefs: